764 related articles for article (PubMed ID: 21997132)
1. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.
Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.
Albain KS; Unger JM; Crowley JJ; Coltman CA; Hershman DL
J Natl Cancer Inst; 2009 Jul; 101(14):984-92. PubMed ID: 19584328
[TBL] [Abstract][Full Text] [Related]
4. Determinants of black/white differences in colon cancer survival.
Mayberry RM; Coates RJ; Hill HA; Click LA; Chen VW; Austin DF; Redmond CK; Fenoglio-Preiser CM; Hunter CP; Haynes MA
J Natl Cancer Inst; 1995 Nov; 87(22):1686-93. PubMed ID: 7473817
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
6. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
[TBL] [Abstract][Full Text] [Related]
9. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
Cheung WY; Shi Q; O'Connell M; Cassidy J; Blanke CD; Kerr DJ; Meyers J; Van Cutsem E; Alberts SR; Yothers G; Sargent DJ;
Clin Colorectal Cancer; 2013 Sep; 12(3):179-87. PubMed ID: 23810482
[TBL] [Abstract][Full Text] [Related]
10. Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer.
Murphy CC; Harlan LC; Warren JL; Geiger AM
J Clin Oncol; 2015 Aug; 33(23):2530-6. PubMed ID: 26150445
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
[TBL] [Abstract][Full Text] [Related]
12. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
Lai Y; Wang C; Civan JM; Palazzo JP; Ye Z; Hyslop T; Lin J; Myers RE; Li B; Jiang B; Sama A; Xing J; Yang H
Gastroenterology; 2016 May; 150(5):1135-1146. PubMed ID: 26836586
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
14. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
15. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
Meyerhardt JA; Shi Q; Fuchs CS; Meyer J; Niedzwiecki D; Zemla T; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Bendell JC; Kumar P; Lewis D; Tan B; Bertagnolli M; Grothey A; Hochster HS; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF
JAMA; 2021 Apr; 325(13):1277-1286. PubMed ID: 33821899
[TBL] [Abstract][Full Text] [Related]
16. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
[TBL] [Abstract][Full Text] [Related]
17. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
Ng K; Ogino S; Meyerhardt JA; Chan JA; Chan AT; Niedzwiecki D; Hollis D; Saltz LB; Mayer RJ; Benson AB; Schaefer PL; Whittom R; Hantel A; Goldberg RM; Bertagnolli MM; Venook AP; Fuchs CS
J Natl Cancer Inst; 2011 Oct; 103(20):1540-51. PubMed ID: 21849660
[TBL] [Abstract][Full Text] [Related]
18. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project.
Dignam JJ; Colangelo L; Tian W; Jones J; Smith R; Wickerham DL; Wolmark N
J Natl Cancer Inst; 1999 Nov; 91(22):1933-40. PubMed ID: 10564677
[TBL] [Abstract][Full Text] [Related]
19. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance).
Lee S; Zhang S; Ma C; Ou FS; Wolfe EG; Ogino S; Niedzwiecki D; Saltz LB; Mayer RJ; Mowat RB; Whittom R; Hantel A; Benson A; Atienza D; Messino M; Kindler H; Venook A; Gross CP; Irwin ML; Meyerhardt JA; Fuchs CS
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34104867
[TBL] [Abstract][Full Text] [Related]
20. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]